Engages in the research, production and distribution of pharmaceutical products Sanofi engages in the research, production and distribution of pharmaceutical products.
The company operates through the following segments: Pharmaceuticals, Human Vaccines and Animal Health.
The Pharmaceuticals segment includes research, development, production and sales activities relating to pharmaceutical products, including prescription, consumer health care, and generic products.
This segment also includes equity affiliates and joint ventures with pharmaceutical business activities.
The Human Vaccines segment includes research, development, production and marketing.
The Animal Health segment comprises the research, development, production and marketing activities for vaccines.
It offers a range of medicines and vaccines on animal species.
The company was founded in 1994 and is headquartered in Paris, France.
Number of employees : 112 128 persons.
2012 2013 Delta USD (in Million) % USD (in Million) % Pharmaceuticals 37,294 82.6% 36,247 82.7% -2.89% Human Vaccines 5,034 11.2% 4,943 11.3% -1.84% Animal Health 2,815 6.2% 2,640 6% -6.6%
2012 2013 Delta USD (in Million) % USD (in Million) % Rest of the World 16,084 35.6% 15,219 34.7% -5.68% United States 14,045 31.1% 13,878 31.7% -1.21% Europe (Excluding France) 10,605 23.5% 10,552 24.1% -0.5% France 3,676 8.1% 3,420 7.8% -7.5% North America 732.42 1.6% 762.19 1.7% +3.91%
Shareholders SANOFI (SAN - Euronext Paris) Sanofi SA (SNY - Nyse) Sanofi SA (US80105N1138)
Name Shares % L'Oréal SA 118,227,307 8.96% Norges Bank Investment Management 28,497,058 2.16% Natixis Asset Management SA 19,865,861 1.51% Plan d'Epargne Entreprise Sanofi Synthelabo 17,366,892 1.32% Dodge & Cox, Inc. 17,325,800 1.31% Amundi SA (Investment Management) 16,215,887 1.23% The Vanguard Group, Inc. 15,427,380 1.17% BlackRock Fund Advisors 10,977,235 0.83% FIL Investments International 10,727,214 0.81% Lyxor International Asset Management SA 10,661,083 0.81%
Name Shares % Dodge & Cox, Inc. 43,664,887 1.66% Barrow, Hanley, Mewhinney & Strauss LLC 27,790,116 1.05% Franklin Advisers, Inc. 14,660,925 0.56% Fisher Asset Management LLC 13,079,575 0.50% Robeco Investment Management, Inc. 11,188,043 0.42% Invesco Advisers, Inc. 10,674,925 0.40% Hotchkis & Wiley Capital Management LLC 9,804,594 0.37% Fidelity Management & Research Co. 5,912,038 0.22% NWQ Investment Management Co. LLC 5,460,055 0.21% Berkshire Hathaway, Inc. (Investment Management) 3,905,875 0.15%
Name Shares % Millennium Management LLC 2,844,120 0.0000% GAMCO Asset Management Inc. 631,351 0.0000% PineBridge Investments LLC 121 0.0000% Horizon Asset Management LLC 15,940 0.0000% Basso Capital Management LP 275,000 0.0000% Archford Capital Strategies LLC 680 0.0000% Serengeti Asset Management LP 1,750,000 0.0000% Ropes & Gray LLP (Private Client Group) 2,607 0.0000% Parasol Investment Management LLC 9 0.0000% New England Securities Corp. 667 0.0000%
Name Shares % Valuation
Regeneron Pharmaceuticals Inc (REGN) 22,204,841 22.5% 6,272,201,437 USD Zentiva SA (ROSCD) 312,341,649 74.9% 114,819,914 USD SANOFI (SAN) 3,632,599 0.28% 385,849,762 USD Nichi-iko Pharmaceutical Co., Ltd. (4541) 2,846,000 4.69% 42,561,475 USD GENFIT (GNFT) 355,299 1.67% 12,647,898 USD Proteome Sciences plc (PRM) 51,000 0.024% 31,393 USD Immune Design Corp. 611,620 3.94% 7,339,440 USD Aventis Pharma Limited (AVPH) 13,909,587 60.4% 722,364,217 USD Sanofi India Ltd (SANOFI) 13,909,587 60.4% 722,364,217 USD GlycoMimetics Inc (GLYC) 1,193,625 6.35% 10,062,259 USD
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Company contact information
Sanofiwww.sanofi.com
© 2014 Factset
